Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Seminars in Immunopathology Année : 2017

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Résumé

Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident T-reg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.
Fichier non déposé

Dates et versions

hal-01607061 , version 1 (02-10-2017)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Franck Carbonnel, Emilie Soularue, Clélia Coutzac, Nathalie Chaput, Christine Mateus, et al.. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. Seminars in Immunopathology, 2017, 39 (3), pp.327-331. ⟨10.1007/s00281-016-0613-x⟩. ⟨hal-01607061⟩
151 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More